How Much Does Mounjaro Cost in Louisiana in 2026?

Mounjaro Retail Pricing in Louisiana

The manufacturer list price set by Eli Lilly for Mounjaro is $1,023.04 per month across all pen doses. That number holds steady whether you fill at a Walgreens in Baton Rouge or a Walmart in Shreveport. Louisiana retail pharmacies have no meaningful price variation from the national average because tirzepatide is distributed through a single-source supply chain with uniform wholesale acquisition cost.

Tirzepatide is dispensed as a prefilled pen in four-unit cartons, each representing one month of once-weekly dosing. The FDA-approved prescribing information specifies a starting dose of 2.5 mg weekly for the first four weeks, then 5 mg weekly, with optional titration up to 15 mg. The list price does not change by dose strength [1]. Patients paying entirely out of pocket in Louisiana face the same $1,023 monthly expense regardless of whether they are on the 2.5 mg starter or the 15 mg maximum.

For comparison, semaglutide 2.4 mg (Wegovy) lists at roughly $1,349 per month [2]. That $326 monthly gap makes Mounjaro the less expensive brand-name GIP/GLP-1 receptor agonist at list price, though real-world costs vary by plan formulary and pharmacy benefit manager contracts.

Louisiana Medicaid and Mounjaro Coverage

Louisiana Medicaid does not cover Mounjaro for weight management as of 2026. Coverage exists only for tirzepatide's type 2 diabetes indication under Louisiana's Medicaid preferred drug list, and prior authorization is required. Patients seeking the drug specifically for obesity will find no Medicaid pathway in Louisiana at this time.

This gap reflects a broader national pattern. The Centers for Medicare & Medicaid Services has noted that most state Medicaid programs exclude anti-obesity medications from coverage, a policy rooted in a 2003 statutory prohibition that many states have not reversed [3]. Louisiana's Medicaid program covers approximately 1.8 million residents. For the subset who carry both obesity and type 2 diabetes, a prescriber may obtain Medicaid approval by documenting the type 2 diabetes diagnosis with HbA1c criteria specified in the ADA Standards of Care [4].

The Endocrine Society's 2024 clinical practice guideline on pharmacologic treatment of obesity recommends tirzepatide as a first-line option for adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities [5]. That recommendation has not yet changed Louisiana Medicaid policy.

Private Insurance Coverage in Louisiana

Commercial insurers in Louisiana vary widely on Mounjaro coverage. Blue Cross Blue Shield of Louisiana, the state's largest private insurer, covers tirzepatide for type 2 diabetes on its preferred formulary tier. Coverage for weight management depends on the specific plan. Many employer-sponsored plans exclude anti-obesity medications entirely.

Patients with commercial coverage should check three things: whether the plan's formulary lists Mounjaro, whether a prior authorization or step therapy requirement applies, and whether the plan excludes weight-loss drugs by category. A 2023 analysis in Obesity found that only 26% of large employer plans covered any anti-obesity medication, though that number has been climbing as clinical trial evidence accumulates [6].

The SURPASS-2 trial (N=1,879) demonstrated that tirzepatide 15 mg reduced HbA1c by 2.58% compared with 1.86% for semaglutide 1 mg at 40 weeks in adults with type 2 diabetes [7]. This head-to-head superiority data has strengthened formulary inclusion arguments. Patients can request a formulary exception by having their prescriber submit SURPASS trial evidence alongside individualized clinical documentation per ADA pharmacologic standards [4].

The Eli Lilly Savings Card

Eli Lilly offers a commercial copay savings card that reduces out-of-pocket cost to as low as $25 per monthly fill for eligible patients. The card applies only to commercially insured patients. It does not work with Medicare, Medicaid, Tricare, or other government-funded programs.

Eligibility requirements are straightforward. The patient must have commercial insurance that covers Mounjaro, must have a valid prescription, and must fill at a participating pharmacy. The savings card covers up to $150 per fill in copay assistance for patients with insurance. Lilly also offers a separate Mounjaro savings program for cash-paying patients, though the cash-pay discount is smaller and subject to change.

Louisiana pharmacies that accept the card include CVS, Walgreens, Walmart, Costco, and most independent pharmacies. Patients activate the card through the Lilly website or through their prescribing clinician. The card benefit resets annually.

Compounded Tirzepatide in Louisiana

Compounded tirzepatide is available through licensed 503A compounding pharmacies in Louisiana at approximately $249 per month. This represents a 76% reduction from the brand-name retail price. Louisiana permits 503A compounding under state pharmacy board regulations that align with FDA guidance on 503A compounding [8].

A 503A pharmacy compounds medications pursuant to individual patient prescriptions. The pharmacist must hold a valid Louisiana Board of Pharmacy license, and the compounded product must use ingredients from FDA-registered suppliers. Compounded tirzepatide is not FDA-approved and does not carry the same regulatory review as branded Mounjaro.

The FDA's position on compounding permits 503A compounding when a prescriber determines a medical need for a specific patient [9]. The drug must appear on the FDA's shortage list or not be a copy of a commercially available product for certain compounding pathways. Tirzepatide's shortage status has fluctuated. Patients considering compounded tirzepatide should confirm the current shortage listing on the FDA drug shortage database [10] and verify that their pharmacy holds current Louisiana Board of Pharmacy accreditation.

Quality control varies between compounding pharmacies. The United States Pharmacopeia (USP) sets standards for sterile compounding under chapters 797 and 800 [11]. Patients should ask their compounding pharmacy whether it follows USP 797 standards and whether it undergoes third-party testing of finished preparations.

Telehealth Access to Mounjaro in Louisiana

Louisiana permits telehealth prescribing of Mounjaro. The state's telehealth statutes allow licensed prescribers to evaluate patients and write prescriptions via synchronous audio-video visits without requiring an initial in-person encounter. This makes tirzepatide accessible to patients in rural parishes where endocrinology or obesity medicine specialists are scarce.

Several national telehealth platforms operate in Louisiana and prescribe tirzepatide. Patients should verify that the prescribing clinician holds an active Louisiana medical license and that the platform uses pharmacies licensed in Louisiana. The American Telemedicine Association has published practice guidelines supporting telehealth for chronic disease management, including obesity [12].

A telehealth visit for Mounjaro typically costs between $50 and $199, depending on the platform and whether the visit is applied to insurance. Some platforms bundle the consultation fee with compounded tirzepatide at an all-in monthly cost. Patients with commercial insurance may have telehealth visits covered under their plan's virtual care benefit.

Cost-Saving Strategies Specific to Louisiana

Louisiana residents have several pathways to reduce Mounjaro costs beyond the Lilly savings card.

Pharmacy benefit optimization. Some Louisiana pharmacies participate in preferred network arrangements with specific PBMs. Filling at a preferred pharmacy can reduce copays by 30% to 50% compared with non-preferred locations. Patients should call their insurer's pharmacy help line to identify preferred pharmacies in their area.

Manufacturer patient assistance. Eli Lilly operates the Lilly Cares Foundation, which provides free Mounjaro to patients who are uninsured, have household income below 400% of the federal poverty level, and do not qualify for government insurance. The application requires income documentation and a prescriber signature.

GoodRx and discount aggregators. Cash-pay discount cards from GoodRx, RxSaver, and similar platforms can reduce the retail price at some Louisiana pharmacies, though discounts on single-source brand drugs like Mounjaro tend to be modest (typically 2% to 8% off list price).

Clinical trials. Active tirzepatide trials may provide the drug at no cost. The SURMOUNT-5 cardiovascular outcomes trial continues to enroll at Louisiana sites [13]. Patients can search for open trials at ClinicalTrials.gov filtered by Louisiana location.

Clinical Evidence Supporting Tirzepatide

Tirzepatide's cost reflects a strong evidence base. The drug is a dual GIP and GLP-1 receptor agonist, a mechanism distinct from GLP-1-only drugs like semaglutide [14].

In SURPASS-2 (N=1,879), tirzepatide 15 mg produced a 2.58% HbA1c reduction versus 1.86% for semaglutide 1 mg at 40 weeks, with 5.5 kg greater weight loss [7]. The SURMOUNT-1 trial (N=2,539) demonstrated 22.5% mean weight loss with tirzepatide 15 mg versus 3.1% with placebo at 72 weeks in adults with obesity without diabetes [15]. That 22.5% figure exceeds the 14.9% weight loss seen with semaglutide 2.4 mg in the STEP-1 trial (N=1,961) [16].

"Tirzepatide represents a meaningful advance in both glycemic control and weight reduction," noted the Endocrine Society's 2024 guideline authors, recommending it alongside semaglutide as a first-line pharmacotherapy for obesity [5].

The American Diabetes Association's 2024 Standards of Care include tirzepatide as a preferred agent for patients with type 2 diabetes who also need weight reduction [4]. These guidelines are the basis for many insurance formulary decisions.

Safety Profile and Monitoring

The most common adverse effects of tirzepatide are gastrointestinal: nausea (up to 31%), diarrhea (17%), and decreased appetite (14%) in the SURPASS program pooled data [7]. These effects are dose-dependent and typically diminish after 4 to 8 weeks of stable dosing. Slow titration per the FDA label reduces GI side effects substantially.

Tirzepatide carries a boxed warning for thyroid C-cell tumors based on rodent data, consistent with other GLP-1 receptor agonists [1]. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Prescribers in Louisiana must document thyroid history before initiation per the FDA label requirements [1].

Patients on tirzepatide should have baseline and periodic monitoring of renal function, lipase/amylase if pancreatitis symptoms arise, and diabetic retinopathy screening for those with type 2 diabetes, per ADA recommendations [4].